Related Experiment Videos
Development and clinical experience with the new evidence-based tocolytic atosiban
1Department of Obstetrics and Gynecology, University of Vienna Medical School, Austria. peter.husslein@akh-wien.ac.at
Acta Obstetricia Et Gynecologica Scandinavica
|August 23, 2002
Summary
The new oxytocin antagonist, atosiban, offers a safer approach to managing preterm labor. This uterine-specific tocolytic shows potential for prolonged treatment and use in patients with contraindications.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
Background:
- Preterm birth incidence remains high due to complex causes and limited efficacy/safety of current tocolytics.
- Existing tocolytic agents have poor safety profiles and limited ability to prolong pregnancy.
- Oxytocin antagonists, like atosiban, represent a new generation of uterine-specific tocolytics with improved safety.
Purpose of the Study:
- To review the development and clinical trial data of atosiban, an oxytocin antagonist.
- To evaluate the efficacy and safety of atosiban in managing preterm labor.
- To explore the potential of atosiban in extending treatment duration and patient eligibility.
Main Methods:
- Review of Phase II and III clinical trials of atosiban.
- Retrospective analysis of 83 women treated with atosiban at Vienna Medical School.
- Assessment of atosiban's benefits in a real-world clinical setting.
Main Results:
- Atosiban demonstrates a more favorable safety profile compared to traditional tocolytics.
- Clinical trials and retrospective analysis suggest benefits in prolonging pregnancy.
- Potential for expanded use in patients with contraindications, such as preterm premature rupture of membranes.
Conclusions:
- Atosiban offers a promising, safer alternative for preterm labor management.
- Its uterine-specific action and improved safety profile may change clinical practice.
- Potential for earlier, later, or extended treatment durations and broader patient applicability.